- Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
- Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
- Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
- Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
- Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
- Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
- Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
More ▼
Key statistics
On Wednesday, Aprea Therapeutics Inc (APRE:NAQ) closed at 3.76, 35.25% above the 52 week low of 2.78 set on Jul 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.72 |
---|---|
High | 3.81 |
Low | 3.70 |
Bid | 3.71 |
Offer | 3.99 |
Previous close | 3.80 |
Average volume | 12.23k |
---|---|
Shares outstanding | 5.43m |
Free float | 4.44m |
P/E (TTM) | -- |
Market cap | 20.42m USD |
EPS (TTM) | -3.32 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:53 BST.
More ▼